Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 22 of 22 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/21/22
End: 04/30/25
Due: 04/30/26
Phase: N/A
Priority: Normal
Start: 10/30/24
End: 04/30/28
Due: 04/30/29
Phase: N/A
Priority: Normal
Start: 09/27/21
End: 02/18/22
Due: 02/18/23
Phase: N/A
Priority: Normal
Start: 12/03/21
End: 04/30/27
Due: 04/30/28
Phase: N/A
Priority: Normal
Start: 08/30/19
End: 06/30/23
Due: 06/30/24
Phase: N/A
Priority: Normal
Start: 01/16/23
End: 01/31/30
Due: 01/31/31
Phase: N/A
Priority: Normal
Start: 07/04/19
End: 04/27/21
Due: 04/27/22
Phase: N/A
Priority: Normal
Start: 03/27/17
End: 10/21/19
Due: 10/21/20
Phase: N/A
Priority: Normal
Start: 01/31/15
End: 05/31/16
Due: 05/31/17
Phase: N/A
Priority: Normal
Start: 05/31/16
End: 01/11/18
Due: 01/11/19
Phase: N/A
Priority: Normal
Start: 03/31/14
End: 07/31/14
Due: 07/31/15
Phase: N/A
Priority: Normal
Start: 10/10/22
End: 04/30/25
Due: 04/30/26
Phase: N/A
Priority: Normal
Start: 01/13/20
End: 03/15/24
Due: 03/15/25
Phase: N/A
Priority: Normal
Start: 12/31/14
End: 12/31/16
Due: 12/31/17
Phase: N/A
Priority: Normal
Start: 09/30/14
End: 06/30/15
Due: 06/30/16
Phase: N/A
Priority: Normal
Start: 07/01/20
End: 04/16/21
Due: 04/16/22
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
Phase: N/A
Priority: Normal
Start: 12/17/20
End: 05/18/21
Due: 05/18/22
Phase: N/A
Priority: Normal
Start: 01/20/18
End: 08/15/22
Due: 08/15/23
Phase: N/A
Priority: Normal
Start: 11/16/17
End: 02/04/19
Due: 02/04/20
Phase: N/A
Priority: Normal
Start: 10/24/19
End: 01/23/23
Due: 01/23/24
Phase: N/A
Priority: Normal
Start: 09/23/19
End: 04/16/21
Due: 04/16/22
Phase: N/A
Priority: Normal
Start: 09/19/22
End: 09/19/22
Due: 09/19/23